ESTRO 2024 - Abstract Book

S2884

Interdiscplinary - Other

ESTRO 2024

survival (OS) among others. QUALYs are a necessary component of economic evaluation and health technology assessment of treatments to inform policy and reimbursement decisions.

Material/Methods:

Histologically proven breast cancer patients, aged ≥ 18 years, of any disease stage, are ≥ 30 days post histopathologic cancer diagnosis, with updated staging work-up not older than 3 months were recruited. The EQ 5D-5L health status measurement tool is a self-administered generic instrument for describing and valuing health, based on a descriptive system that defines health in terms of 5 dimensions, namely: Mobility, Self- Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension is evaluated in terms of five levels of severity: no problems, slight problems, moderate problems, severe problems, extreme problems/unable to. The EQ-5D data was converted to HSUV from a locally validated value set. Student’s t-test and one-way analysis of variance (ANOVA) were utilized to compare the HRQoL among breast cancer patients on different treatment modalities and stages. Multiple linear regression was employed to identify significant predictors of the HRQoL among breast cancer patients. From June 2022 to August 2022, a total of 172 patients were surveyed with a median age of 51 years (IQR 43, 59). Of the 170 patients analyzed, disease stage were noted to be stage I, II, III and IV for 4 (2.4%), 44 (25.9%), 78 (45.9%), and 44 (25.9%) patients, respectively. The disease management status were noted to be biopsy only in 12.4% (n= 21), post-surgery in 7.1% (n= 12), ongoing chemotherapy in 54.7% (n= 93), post-chemotherapy in 5.3% (n= 9), ongoing radiotherapy in 2.9% (n= 5), post-radiotherapy in 1.2% (n= 2), and undergoing surveillance in 16.5% (n= 28) of the patients. Treatment intent was curative in 74.7% while it was palliative in 24.7% of the patients. An HSUV of 0.796 (0.075), 0.877 (0.102), 0.855 (0.144), and 0.787 (0.204) was noted for stage I, II, III and IV, respectively. The mean HSUV for the cohort when grouped according to their disease management status at the time of survey (p= 0.741) were noted to be 0.860 (SD 0.077) for biopsy only, 0.784 (SD 0.165) for post-surgery, 0.848 (0.162) for ongoing chemotherapy, 0.800 (0.241) for post-chemotherapy, 0.789 (0.189) for ongoing radiotherapy, 0.885 (0.067) for post-radiotherapy, and 0.852 (0.138) for patients on surveillance. Significant differences in the mean HSUV in their subcategories were noted for disease stage (p = 0.32), radiotherapy regimen received (p = 0.046), and ECOG performance status (p < 0.001). On multiple linear regression analysis, age was the only significant predictor of HSUV, with a 0.004 disutility for every increase in age. Results:

Conclusion:

This is the first study utilizing the locally validated version of the EQ-5D-5L survey and local EQ-5D value set to arrive at HSUV values for Filipino patients with breast cancer. Health utility among breast cancer patients were noted to be significantly influenced by their disease stage, radiotherapy regimen received, and ECOG performance status while age was the only significant predictor of disutility on multiple linear regression analysis, with a 0.004 disutility for every increase in age.

Keywords: Health state utility values, breast cancer, EQ5D5L

References:

1. World Health Organization (WHO). Philippine Fact Sheets (Cancer). Glob Cancer Stat [Internet]. 2020;163:1–2. Available from: https://www.uicc.org/news/globocan-2020-new-global-cancer-data